For example, analysis of patient responses to amivantamab, an EGFR/c-MET bsAb approved for NSCLC, revealed resistance mechanisms including c-MET/EGFR amplification and PIK3CA mutations [61]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.